An observational study in Sepsis and Acute Lung Injury(ALI), sponsored by University of Kentucky. Recruiting at 1 site in United States. Open to participants aged 18 Years to 99 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by University of Kentucky · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 517 studies in Sepsis with a site in United States — 74 open to participants now, 99 under way, 3 of them phase 3. Sepsis · United States.
Among the 517 studies in Sepsis with a site in United States, this one is the 109th largest by planned enrollment of the 204 observational ones that give a count, is one of 29 that started in 2026, is one of 204 observational ones, reaches primary completion later than 90 of the 98 other live ones, and was the 489th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →74 of the 517 studies in Sepsis with a site in United States are open now. Recruiting first, the newest first:
Deepull Diagnostics S.L. · Sites in United States, France, Germany and 2 more countries
Intermountain Health Care, Inc. · Sites in United States
Ages 18+
Bassett Healthcare · Sites in United States
Ages 18+
Duke University · Sites in United States
Ages 0 days–7 days
Vanderbilt University Medical Center · Sites in United States
Ages 1 days–12 mo
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 99 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
517 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 50 · Phase 2 80 · Phase 3 47 · Phase 4 25
First in 1988; this study’s year is marked. 29 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is close to the median of 150 across 1,166 observational studies indexed under Sepsis.
Median enrollment 84 across the 310 interventional studies, 183 across the 204 observational. Of the 361 that completed or were terminated, 117 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
135 of 517 have an industry lead sponsor. The 10 most frequent:
University of Kentucky is the lead sponsor of 68 studies on the registry; 7 are open to participants now.
University of Kentucky has 1 study filed under Sepsis — fewer than ten, so there is no comparison to draw.
37 of the studies in Sepsis with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06817408Mayo ClinicDynamics of Organ Damage and Immune Exhaustion During Sepsis | 2026-12 |
| NCT04796285Brigham and Women's HospitalA Validation Study of the Lab Clasp Device: A Point of Care Sepsis Risk Monitor | 2026-12 |
| NCT01315782The University of Texas Health Science Center, HoustonAlveolar Dead Space as Predictor of Organ Failure in Severe Sepsis | 2026-12 |
| NCT06692400Loma Linda UniversityThe Effects of Endotracheal Suctioning on Pain and Serum Markers | 2026-12 |
| NCT03133208University of FloridaSepsis Associated Encephalopathy (SAE) Biomarkers | 2026-12-15 |
Add all 37 to your calendar (.ics) → With an account.
Among the 517 studies in Sepsis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The proposed study is a prospective, observational study assessing the recovery of muscle and physical function in patients surviving critical illness (n =150) at hospital discharge (baseline) and repeated serially. Patients will be enrolled after life-saving modalities have been weaned near hospital discharge. Patients will participate in testing at baseline, 3-, 6-, 12-, and 24-months after hospital discharge. In a subset of patients (n = 18), muscle biopsies will be performed at baseline and then repeated once at either 12- or 24-months after hospital discharge.
The overarching goal of the proposed study is to determine the trajectories of physical recovery and cellular markers involved with the underlying failure to recover muscle after critical illness, while exploring which characteristics are associated with sustained physical disability. This proposal will examine muscle pathophysiology carefully aligned with physical function outcomes in order to longitudinally assess the recovery, or failed recovery, of muscle function in participants after critical illness:
Aim 1: Determine the long-term trajectory of muscle strength, physical function and ADL recovery in ICU survivors. Patients (n = 150) will participate in a battery of tests to determine muscle and physical function aligned with self-reported measures of ADLs and quality of life at hospital discharge, 3-, 6-, 12-, and 24-months post.
Aim 2: Assess cellular changes in skeletal muscle in ICU survivors contributing to long-term physical dysfunction. In a subgroup of patients enrolled in Aim 1, muscle biopsies will be collected at baseline and long-term follow-up to determine oxidative stress, mitochondrial function, and cellular senescence.
Adults with a diagnosis of acute lung injury or sepsis who have survived an Intensive Care Unit admission for at least 72 hours.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Survivors of critical illness
Muscle Strength measured by Chair Rise Test
Performance on 5x sit to stand test will be the primary outcome measure representing lower extremity muscle strength ; measured as time in seconds to complete 5 repetitive sit-stands.
Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.
Functional Capacity
The 6-minute walk test (6MWT), which measures the distance a participant can walk in six minutes and serves as an indicator of cardiopulmonary function, will be used as a primary outcome.
Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.
Muscle morphology # 1
Myofiber size
Time frame: Percent change from baseline to 12 months
Muscle morphology #2
Myofiber type
Time frame: Percent change from baseline to 12 months
Lower-extremity Muscle Power
Muscular Power: Power will be assessed using a linear potentiometer (HUMAC-360, CSMi, Stoughton, MA) to record the velocity and peak-velocity of a functional movement using a Shuttle MiniPress (Shuttle Systems, Bellingham, WA) as hamstring/gluteal pressdown. Outcome measure is Watts.
Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.
Muscle Size and Quality measured by Ultrasound
Ultrasound imaging will be performed to acquire images of quadriceps and tibialis anterior to measure muscle cross-sectional area, muscle thickness and echo intensity of muscles.
Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.
Activities of Daily Living (ADL)
Katz ADL will be used to assess ADL. The range of scores are 0 - 6 with a higher score being an better outcome.
Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.
Health Reported Quality of Life
5 Dimension Euro-Quality of Life (EQ-5D) is a self-report instrument including 5 questions and a visual analog scale (0-100) used to measure subjective quality of life with a higher score being a better outcome.
Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.
Fatigue
The Functional Assessment of Chronic Illness Therapy (FACIT-fatigue instrument) will be used to measure subjective fatigue and quality of life. All items are summed to create a single score with a range from 0 to 52. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning and a higher quality of life.
Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.
Physical Frailty
Physical frailty will be quantified using Fried Frailty Phenotype with five criteria (weight loss, weakness, exhaustion, gait speed, and physical activity) and the Clinical Frailty Scale. Scoring is 0-5 with: ≥3/5 criteria met indicates frailty; 1-2/5 indicates pre-or-intermediate frailty; 0/5 indicates non-frail.
Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.
Physical Activity
Patients will wear an Actigraph (Garmin, Vivofit 4) or an Oura ring to measure the number of steps per day. The outcome measure will be average number of steps per day over a seven day period.
Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.
Muscle strength of quadriceps
Strength of quadriceps muscle will be recorded using a hand-held dynamometry, Lafayette Manual Muscle Test System Model-01165 (Lafayette Company, Lafayette, IN). Outcome is measured in kilograms.
Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.
Grip Strength
Hand grip strength will be assessed with a handgrip dynamometry (HGD), Jamar Hydraulic dynamometer (Sammons Preston Rolyan, Bolingbrook, IL, USA). Outcome is measured in kilograms (kgs).
Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.
Physical function
The Short Physical Performance Battery (SPPB) assesses balance, repeated sit-to-stand performance, and 4-meter gait speed. Each component is scored and converted to an ordinal scale, with the total score ranging from 0 to 12.
Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.
Physical function
Timed-up and Go Test (TUG), which is a measure of mobility and fall risk requiring patients to stand from a chair and walk short-distance for time in seconds.
Time frame: Baseline and repeated 3-, 6-, 12-, and 24-months after baseline assessment.
Plan to share: Undecided — Not yet decided.
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Jun 2030, 50 months after the start.
Of 496 non-industry observational studies under Sepsis, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 57. This study's planned 50 months is above that.
Counting every sponsor, half of 548 studies reached it within 27 months; a quarter within 12 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Kentucky